Nature communications · 2024
Converging and evolving immuno-genomic routes toward immune escape in breast cancer.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Blanco-Heredia Juan, Souza Carla Anjos, Trincado Juan L, Gonzalez-Cao Maria, Gonçalves-Ribeiro Samuel, Gil Sara Ruiz, Pravdyvets Dmytro, Cedeño Samandhy, Callari Maurizio, Marra Antonio, Gazzo Andrea M, Weigelt Britta, Pareja Fresia, Vougiouklakis Theodore, Jungbluth Achim A, Rosell Rafael, Brander Christian, Tresserra Francesc, Reis-Filho Jorge S, Tiezzi Daniel Guimarães, de la Iglesia Nuria, Heyn Holger, De Mattos-Arruda Leticia
Аннотация
The interactions between tumor and immune cells along the course of breast cancer progression remain largely unknown. Here, we extensively characterize multiple sequential and parallel multiregion tumor and blood specimens of an index patient and a cohort of metastatic triple-negative breast cancers. We demonstrate that a continuous increase in tumor genomic heterogeneity and distinct molecular clocks correlated with resistance to treatment, eventually allowing tumors to escape from immune control. TCR repertoire loses diversity over time, leading to convergent evolution as breast cancer progresses. Although mixed populations of effector memory and cytotoxic single T cells coexist in the peripheral blood, defects in the antigen presentation machinery coupled with subdued T cell recruitment into metastases are observed, indicating a potent immune avoidance microenvironment not compatible with an effective antitumor response in lethal metastatic disease. Our results demonstrate that the immune responses against cancer are not static, but rather follow dynamic processes that match cancer genomic progression, illustrating the complex nature of tumor and immune cell interactions.